Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Oct 20:6:35410.
doi: 10.1038/srep35410.

Hepatitis C RNA assay differences in results: Potential implications for shortened therapy and determination of Sustained Virologic Response

Gavin Cloherty  1 , Stephane Chevaliez  2 , Christoph Sarrazin  3 , Christine Herman  1 , Vera Holzmayer  1 , George Dawson  1 , Benjamin Maasoumy  4 , Johannes Vermehren  4 , Heiner Wedemeyer  3 , Jordan J Feld  5 , Jean-Michel Pawlotsky  2
Affiliations

Hepatitis C RNA assay differences in results: Potential implications for shortened therapy and determination of Sustained Virologic Response

Gavin Cloherty et al. Sci Rep. .

Abstract

Approval of Ledipasvir/Sofosbuvir for the treatment of chronic hepatitis C (HCV) includes the truncation of therapy from 12 to 8 weeks in treatment naïve, non-cirrhotic patients with baseline HCV RNA levels <6 million IU/mL (6.8 log10 IU/mL). The aim of this study was to evaluate this clinical cutoff with a different widely used commercially available HCV RNA test. Results from samples tested prospectively with Roche High Pure TaqMan HCV 2.0 test (HPS) were compared to those tested retrospectively with the Abbott RealTime HCV RNA test (ART). Using 6 million IU/mL as the cut-off, pre-treatment results were concordant in 70.4% of cases. When results with the same test measured at screening and baseline, clinical decisions could be impacted in 14.4% and 6.2% of cases for HPS and ART respectively. Using only HCV RNA cutoff of 6 million IU/mL, 29.55% of subjects would receive a different and potentially incorrect treatment duration based solely on HCV RNA test method used. A further 6-14% of subjects would have treatment decision change based on the day the sample was taken.

Trial registration: ClinicalTrials.gov NCT01716585.

PubMed Disclaimer

Conflict of interest statement

Gavin Cloherty, Kevin Cheng, Christine Herman, Vera Holzmayer, George Dawson and John Hackett are employees and shareholders of Abbott Laboratories. Heiner Wedemeyer has received honoraria for consulting or speaking engagements from Abbott, Abbvie, Biolex, Bristol-Myers Squibb, Boehringer Ingelheim, Eiger Pharmaceuticals, Falk Foundation, Gilead Sciences, ITS, JJ/Janssen-Cilag/Janssen TE, Medgenics, Merck/ Schering-Plough, Novartis, Novaria, Roche, Roche Diagnostics, Siemens, Transgene and ViiV. Jean-Michel Pawlotsky has received research grants from Gilead Sciences and has served as an advisor fror Abbott, Abbvie, Achillon, Boehringer-Ingelheim, Bristol-Myers Squibb, Gilead Sciences, Idenix, Janssen, Merck, Novartis and Roche. Christoph Sarrazin has received speaker fees, advisory boards and research support from Abbvie, Roche, Siemens and Qiagen. Stephen Chevaliez has received research grants from Gilead Sciences and has served as an advisor for Gilead Sciences and Roche Pharmaceuticals. Jordan Feld has received consulting fees from Abbvie, Abbott, BMS, Gilead, Janssen, Merck, Theravance. Research support from Abbvie, Abbott, BI, BMS, Gilead, Janssen, Merck, Santaris. Benjamin Maasoumy has received speaker and/or consulting fees from Abbott Molecular, Roche, MSD/Merck, BMS, Fujirebio, Janssen-Cilaq. Research support from Roche and Abbott Molecular. Travel grants from Janssen-Cilaq and Gilead. Johannes Vermehren has received consulting and lecture fees from Abbott, AbbVie, Bristol-Myers Squibb, Covidien, Gilead.

Figures

Figure 1
Figure 1. Breakdown of samples tested with both Roche High Pure HCV RNA 2.0 and Abbott RealTime HCV RNA tests by timepoint.
Figure 2
Figure 2. Least-Squares regression between Abbott RealTime HCV vs Roche HPS/TaqMan 2.0 for all data points within the dynamic range of both assays.
Clinically significant discordant results are found in red box.
Figure 3
Figure 3. Bland Altman Bias Plot Abbott RealTime HCV vs Roche HPS/TaqMan 2.0 for samples with viral load 25 IU/mL or Greater (n = 1011).
The mean difference between the two assays was −0.50 (95% Confidence Interval: −0.53 and −0.48; p < 0.0001) log10 IU/mL HCV RNA.
Figure 4
Figure 4. ROC analysys of all available pre-treatment viral load measurements with both Roche HPS/TaqMan 2.0 HCV and Abbott RealTime HCV assays.
For this analysis Roche HPS/TaqMan 2.0 HCV was considered gold standard.
Figure 5
Figure 5. Samples with Roche HPS/TaqMan 2.0 HCV results falling within log intervals of the assays dynamic range were adjusted based on the calculated negative bias observed with the Abbott RealTime HCV test.
The linear regression of mean expected results compared to the mean expected results adjusted for bias.
Figure 6
Figure 6
(a) Percent detected by Abbott RealTime HCV (ART) and Roche HPS/TaqMan 2.0 HCV using 25 IU/mL as cut-off. DBD = Double Blind Day; OLW = Open Label Week; PSTW = Post Treatment Week. (b) Percent detected by Abbott RealTime HCV (ART) and Roche HPS/TaqMan 2.0 HCV using 100 IU/mL as cut-off. DBD = Double Blind Day; OLW = Open Label Week; PSTW = Post Treatment Week.
See this image and copyright information in PMC

References

    1. Gower E. et al. Global epidemiology and genotype distribution of the hepatitis C virus infection. J Hepatol 61, 45–57 (2014). - PubMed
    1. Wise M. et al. Changing trends in hepatitis C–related mortality in the United States, 1995–2004. Hepatology 47, 1128–1135 (2008). - PubMed
    1. The Global Burden of Hepatitis C Working Group. The Global Burden of Hepatitis C. J Clinical Pharmacology 44, 20–29 (2004). - PubMed
    1. Afdhal N. et al. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med 370, 1483–1493 (2014). - PubMed
    1. Afdhal N. et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med 370, 1889–1898 (2014). - PubMed

MeSH terms

Associated data

LinkOut - more resources